208 related articles for article (PubMed ID: 33122192)
1. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms.
Stefano JE; Lord DM; Zhou Y; Jaworski J; Hopke J; Travaline T; Zhang N; Wong K; Lennon A; He T; Bric-Furlong E; Cherrie C; Magnay T; Remy E; Brondyk W; Qiu H; Radošević K
J Biol Chem; 2020 Dec; 295(52):18379-18389. PubMed ID: 33122192
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
Geoghegan JC; Diedrich G; Lu X; Rosenthal K; Sachsenmeier KF; Wu H; Dall'Acqua WF; Damschroder MM
MAbs; 2016; 8(3):454-67. PubMed ID: 26854859
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a soluble form of human CD73 with ecto-5'-nucleotidase activity.
Heuts DP; Weissenborn MJ; Olkhov RV; Shaw AM; Gummadova J; Levy C; Scrutton NS
Chembiochem; 2012 Nov; 13(16):2384-91. PubMed ID: 22997138
[TBL] [Abstract][Full Text] [Related]
5. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
[TBL] [Abstract][Full Text] [Related]
6. The first CD73-instructed supramolecular hydrogel.
Wu D; Du X; Shi J; Zhou J; Zhou N; Xu B
J Colloid Interface Sci; 2015 Jun; 447():269-72. PubMed ID: 25524006
[TBL] [Abstract][Full Text] [Related]
7. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.
Zhong EH; Ledderose C; De Andrade Mello P; Enjyoji K; Lunderberg JM; Junger W; Robson SC
Am J Physiol Cell Physiol; 2021 Jan; 320(1):C15-C29. PubMed ID: 33052071
[TBL] [Abstract][Full Text] [Related]
9. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells.
Barry F; Boynton R; Murphy M; Haynesworth S; Zaia J
Biochem Biophys Res Commun; 2001 Nov; 289(2):519-24. PubMed ID: 11716504
[TBL] [Abstract][Full Text] [Related]
10. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
11. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.
Gammelgaard OL; Terp MG; Renn C; Labrijn AF; Hamaker O; Nielsen AY; Vever H; Hansen SW; Gjerstorff MF; Müller CE; Parren PW; Ditzel HJ
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096528
[TBL] [Abstract][Full Text] [Related]
12. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract][Full Text] [Related]
13. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
15. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
Stagg J; Divisekera U; McLaughlin N; Sharkey J; Pommey S; Denoyer D; Dwyer KM; Smyth MJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1547-52. PubMed ID: 20080644
[TBL] [Abstract][Full Text] [Related]
17. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
18. Ecto-enzyme and signaling functions of lymphocyte CD73.
Resta R; Yamashita Y; Thompson LF
Immunol Rev; 1998 Feb; 161():95-109. PubMed ID: 9553767
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
[TBL] [Abstract][Full Text] [Related]
20. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]